Title (en) ANTI-CXCL9, ANTI-CXCL10, ANTI-CXCL11, ANTI-CXCL13, ANTI-CXCR3 AND ANTI-CXCR5 AGENTS FOR INHIBITION OF INFLAMMATION

Title (de) ANTI-CXCL9-, ANTI-CXCL10-, ANTI-CXCL11-, ANTI-CXCL13-, ANTI-CXCR3- UND ANTI-CXCR5-WIRKSTOFFE ZUR HEMMUNG VON ENTZÜNDUNGEN

Title (fr) AGENTS ANTI-CXCL9, ANTI-CXCL10, ANTI-CXCL11, ANTI-CXCL13, ANTI-CXCR3 ET ANTI-CXCR5 POUR L'INHIBITION DE L'INFLAMMATION

Publication EP 2866830 A4 20151209 (EN)

Application EP 12880044 A 20120627

Priority US 2012044464 W 20120627

Abstract (en) [origin: WO2014003742A1] Methods for preventing or inhibiting inflammation in a subject are disclosed. In one aspect, the method comprises administering to a subject diagnosed with an inflammatory disease an effective amount of an anti-inflammatory agent that (1) inhibits the expression of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and/or CXCR5, or (2) inhibits the interaction between CXCR3 and CXCL9, CXCL10 or CXCL11, or between CXCR5 and CXCLl 3, or (3) inhibits a biological activity of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and/or CXCR5, wherein the agent comprises an antibody, antibody fragment, short interfering RNA (siRNA), aptamer, synbody, binding agent, peptide, aptamer-siRNA chimera, single stranded antisense oligonucleotide, triplex forming oligonucleotide, ribozyme, external guide sequence, or an agent-encoding expression vector.

IPC 8 full level A61K 39/395 (2006.01); A61K 48/00 (2006.01); A61P 29/00 (2006.01)

CPC (source: EP) A61P 1/04 (2018.01); A61P 3/10 (2018.01); A61P 5/14 (2018.01); A61P 9/10 (2018.01); A61P 11/00 (2018.01); A61P 11/02 (2018.01); A61P 11/06 (2018.01); A61P 13/08 (2018.01); A61P 13/10 (2018.01); A61P 13/12 (2018.01); A61P 17/00 (2018.01); A61P 17/06 (2018.01); A61P 19/02 (2018.01); A61P 21/04 (2018.01); A61P 25/00 (2018.01); A61P 29/00 (2018.01); A61P 31/04 (2018.01); A61P 37/02 (2018.01); A61P 37/06 (2018.01); A61P 37/08 (2018.01); C07K 16/24 (2013.01); A61K 2039/505 (2013.01)

Citation (search report) • [A] WO 2004045525 A2 20040603 - MOREHOUSE SCHOOL OF MEDICINE [US] • [A] WO 2012082494 A2 20120621 - MOREHOUSE SCHOOL OF MEDICINE [US], et al • [I] DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2005 (2005-03-01), GLABINSKI ANDRZEJ ET AL: "Modulation of brain immune-mediated inflammation with anti-chemokine antibodies", XP002747239, Database accession no. PREV200510320434 & FASEB JOURNAL, vol. 19, no. 5, Suppl. S, Part 2, March 2005 (2005-03-01), EXPERIMENTAL BIOLOGY 2005 MEETING/35TH INTERNATIONAL CONGRESS OF PHYSIOLOGICAL SCIENCES; SAN DIEGO, CA, USA; MARCH 31 -APRIL 06, 2005, pages A1443, ISSN: 0892-6638 • [A] JENNY L. HARDISON ET AL.: "The chemokines CXCL9 and CXCL10 promote a protective immune response but do not contribute to cardiac inflammation following infection with Trypanosoma cruzi", INFECTION AND IMMUNITY, vol. 74, no. 1, January 2006 (2006-01-01), pages 125 - 134, XP002747240 • [A] FLIER J ET AL: "Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation", JOURNAL OF PATHOLOGY, JOHN WILEY & SONS LTD, GB, vol. 194, no. 4, 1 August 2001 (2001-08-01), pages 398 - 405, XP002432876, ISSN: 0022-3417, DOI: 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S • [A] RUSCHPLER PETER ET AL: "High CXCR3 expression in synovial mast cells associated with CXCL9 and CXCL10 expression in inflammatory synovial tissues of patients with rheumatoid arthritis", ARTHRITIS RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 5, no. 5, 26 June 2003 (2003-06-26), pages R241 - R252, XP021011812, ISSN: 1465-9905, DOI: 10.1186/AR783 • See also references of WO 2014003742A1

Citation (examination) • DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 2008 (2008-04-01), HARDI ROBERT ET AL: "A phase 1 open-label, single-dose, dose-escalation study of Mdx-1100, a high-affinity, neutralizing, fully human Igg1 kappa anti-CXCL10 (Ip10) monoclonal antibody, in ulcerative colitis", Database accession no. PREV200800413054 & GASTROENTEROLOGY, vol. 134, no. 4, Suppl. 1, April 2008 (2008-04-01), DIGESTIVE DISEASE WEEK MEETING/109TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL- ASSOCIATION; SAN DIEGO, CA, USA; MAY 17 -22, 2008, pages A99 - A100, ISSN: 0016-5085 • LACHER ET AL: "Association of a CXCL9 polymorphism with pediatric Crohn's disease", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 363, no. 3, 6 October 2007 (2007-10-06), pages 701 - 707, XP022288917, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2007.09.020 • HOSOMI S ET AL: "S1705 Increased Numbers of Immature Plasma Cells in Peripheral Blood Overexpress Chemokine Receptor Cxcr3 and Cxcr4 in Ulcerative Colitis", GASTROENTEROLOGY, W.B. SAUNDERS CO, US, vol. 136, no. 5, 1 May 2009 (2009-05-01), pages A - 253, XP026111698, ISSN: 0016-5085, [retrieved on 20090501], DOI: 10.1016/S0016-5085(09)61151-3 • EGESTEN ARNE ET AL: "The proinflammatory CXC-chemokines GRO-[alpha]/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids", INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, SPRINGER VERLAG, BERLIN, DE, vol. 22, no. 12, 1 December 2007 (2007-12-01), pages 1421 - 1427, XP036332319, ISSN: 0179-1958, [retrieved on 20071201], DOI: 10.1007/S00384-007-0370-3 • UDAI SINGH ET AL: "CXCR3 Axis: Role in Inflammatory Bowel Disease and its Therapeutic Implication", ENDOCRINE, METABOLIC & IMMUNE DISORDERS - DRUG TARGETS, vol. 7, no. 2, 1 June 2007 (2007-06-01), NL, pages 111 - 123, XP055360654, ISSN: 1871-5303, DOI: 10.2174/187153007780832109 • DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2005 (2005-03-01), SINGH UDAI P ET AL: "Colitis in IL-10-/- mice is mediated in part by CXCL10 production by CD4+T cells, neutrophils, and NK cells as well as CXCR3+ dendritic cells", Database accession no. PREV200510321754 & FASEB JOURNAL, vol. 19, no. 4, Suppl. S, Part 1, March 2005 (2005-03-01), EXPERIMENTAL BIOLOGY 2005 MEETING/35TH INTERNATIONAL CONGRESS OF PHYSIOLOGICAL SCIENCES; SAN DIEGO, CA, USA; MARCH 31 -APRIL 06, 2005, pages A7 - A8, ISSN: 0892-6638 • S. HOSOMI ET AL: "Increased numbers of immature plasma cells in peripheral blood specifically overexpress chemokine receptor CXCR3 and CXCR4 in patients with ulcerative colitis", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 163, no. 2, 19 November 2010 (2010-11-19), GB, pages 215 - 224, XP055509681, ISSN: 0009-9104, DOI: 10.1111/j.1365-2249.2010.04290.x • ANTHONY T. CORCORAN ET AL: "Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens", WORLD JOURNAL OF UROLOGY., vol. 31, no. 1, 24 March 2012 (2012-03-24), DE, pages 241 - 246, XP055246159, ISSN: 0724-4983, DOI: 10.1007/s00345-012-0852-y • OGAWA T ET AL: "CXCR3 Binding Chemokine and TNFSF14 Over Expression in Bladder Urothelium of Patients With Ulcerative Interstitial Cystitis", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 183, no. 3, 1 March 2010 (2010-03-01), pages 1206 - 1212, XP026938446, ISSN: 0022-5347, [retrieved on 20100301], DOI: 10.1016/J.JURO.2009.11.007

Designated contracting state (EPC) AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication) WO 2014003742 A1 20140103; CN 104870013 A 20150826; CN 112807427 A 20210518; EP 2866830 A1 20150506; EP 2866830 A4 20151209; HK 1212628 A1 20160617; JP 2015524793 A 20150827

DOCDB simple family (application) US 2012044464 W 20120627; CN 201280075412 A 20120627; CN 201710770034 A 20120627; EP 12880044 A 20120627; HK 16100682 A 20160121; JP 2015520137 A 20120627